BACKGROUND Cardiovascular (CV) clinical trials are instrumental in understanding
treatment effects and offer insights into the natural progression of CV disease. Biomarkers …

Context: There is a need to define the exact benefits and contraindications of use of high-
dose recombinant human erythropoietin (EPO) for its non-hematopoietic function as a …

Background Data from next generation sequencing technologies uncovered the existence of
many classes of small RNAs. Recent studies reported that small RNAs are released by cells …

Background Atherosclerosis is a chronic lipid-driven inflammatory disease with infiltration of
low-density lipoprotein and is considered as the pivotal step in plaque formation. The aim of …

We sought to measure serum salusin-α levels in patients with coronary artery disease (CAD)
and to assess their correlation with the severity of the disease. We enrolled 172 patients with …

Atherosclerosis is a systemic disease affecting all vascular beds. The atherosclerotic plaque,
as a first manifestation of the disease, involves a complex pathophysiological mechanism …

Coronary heart disease (CHD) is a prevalent heart disease with the high incidence and
mortality rates worldwide, and its pathogenesis is related to genetic factors. L3MBTL3 has …

A number of studies have suggested that interleukin 6 (IL-6) and interferon-gamma (IFN-γ)
have pathophysiologic roles in cardiovascular diseases. In view of recent evidence that …

Because a useful biomarker for painless myocardial infarction (MI) has yet to be identified,
the aim of this study was to identify a biomarker for diabetic patients with painless MI. A case …

Régulation de l'expression de petits ARN dérivés des RNY dans les lésions
athérosclérotiques. Les LDL de la circulation sanguine s' accumulent dans la paroi …